Metabolic Effects of a Green Tea Extract in Multiple Sclerosis Patients
ClinicalTrials.gov ID
NCT01417312
Lead Sponsor
Charite University, Berlin, GermanyOTHER
Overall Status
Completed
Study Type
Interventional
Phase
Not Applicable
Enrollment
20Actual
Last Update Posted
Jul 29, 2021Actual
Start Date
Jul 2011
Primary Completion Date
Nov 2012Actual
Completion Date
Jan 2013Actual
Brief Summary
This study aims to investigate metabolic effects of a standardized green tea extract, containing a defined amount of epigallocatechin-3-gallate (EGCG), in multiple sclerosis patients.
Multiple Sclerosis, Relapsing-Remitting
Capsules with 160 mg Teavigo (at least 94% EGCG)
Placebo
Ages Eligible for Study
Adult (18-64)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with relapsing-remitting multiple sclerosis
stable treatment with glatiramer acetate at least 6 months prior to inclusion
Expanded disability status scale < 4.5
Normal weight, overweight
Exclusion Criteria:
Primary or secondary progressive forms of multiple sclerosis
Franz-Volhard Clinical Research Center at the Experimental and Clinical Research Center, Charité University Medicine Berlin and Max Delbrueck Center for Molecular Medicine